Prospective Grant of Exclusive License: Development of a Small Molecule Farnesoid X Receptor Inhibitor

Resumo

This notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Cancer Institute (NCI), National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in the following U.S. Patents and Patent Applications to Heliome Biotech, Inc. ("Heliome") located in New York, NY, USA. Intellectual Property: